Publication: Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis
| dc.contributor.coauthor | Gervais, A | |
| dc.contributor.coauthor | Marchal, A | |
| dc.contributor.coauthor | Boucherit, S | |
| dc.contributor.coauthor | Abi, Haidar A | |
| dc.contributor.coauthor | Bizien, L | |
| dc.contributor.coauthor | Yalçınkaya, A | |
| dc.contributor.coauthor | Sandström, E | |
| dc.contributor.coauthor | Kong, XF | |
| dc.contributor.coauthor | Jacquemin, E | |
| dc.contributor.coauthor | Bernard, O | |
| dc.contributor.coauthor | Debray, D | |
| dc.contributor.coauthor | Lacaille, F | |
| dc.contributor.coauthor | Ichai, P | |
| dc.contributor.coauthor | Javouhey, E | |
| dc.contributor.coauthor | Roquelaure, B | |
| dc.contributor.coauthor | Gottrand, F | |
| dc.contributor.coauthor | Trespidi, F | |
| dc.contributor.coauthor | Codullo, V | |
| dc.contributor.coauthor | Cavagna, L | |
| dc.contributor.coauthor | Schleinitz, N | |
| dc.contributor.coauthor | Bousfiha, M | |
| dc.contributor.coauthor | Amenzoui, N | |
| dc.contributor.coauthor | Bousfiha, AA | |
| dc.contributor.coauthor | Jørgensen, SE | |
| dc.contributor.coauthor | Mørk, N | |
| dc.contributor.coauthor | Mogensen, TH | |
| dc.contributor.coauthor | Bastard, P | |
| dc.contributor.coauthor | Puel, A | |
| dc.contributor.coauthor | Borghesi, A | |
| dc.contributor.coauthor | Rule, JA | |
| dc.contributor.coauthor | Lee, WM | |
| dc.contributor.coauthor | Landegren, N | |
| dc.contributor.coauthor | Cobat, A | |
| dc.contributor.coauthor | Casanova, JL | |
| dc.contributor.coauthor | Jouanguy, E. | |
| dc.contributor.department | School of Medicine | |
| dc.contributor.department | KUTTAM (Koç University Research Center for Translational Medicine) | |
| dc.contributor.kuauthor | Arıkan, Çiğdem | |
| dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
| dc.contributor.schoolcollegeinstitute | Research Center | |
| dc.date.accessioned | 2026-07-02T07:28:50Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Fulminant viral hepatitis (FVH) is a devastating condition caused by hepatotropic viruses such as hepatitis A virus (HAV), hepatitis B virus (HBV), and HSV-1/2. We studied 149 FVH patients (73 males and 76 females, aged 1-76) for blood autoantibodies (auto-Abs) neutralizing type I interferons (IFNs; IFN-α2, -β, -ω). Six of 16 (37.5%) HSV-triggered FVH patients carried such auto-Abs on admission, including three with a previously known autoimmune disease. These patients contrasted with 133 HAV- (n = 46) or HBV-triggered (n = 87) patients, none of whom had such detectable auto-Abs. Odds ratios for HSV-triggered FVH in individuals with auto-Abs ranged from 35.3 (95% CI: 13.0-96.2; P < 10-7) for those neutralizing only 100 pg/ml IFN-α/ω to 1,895 (CI: 448.5-8,002; P < 10-12) for those neutralizing both IFN-α and IFN-ω at 10 ng/ml. Over one third of HSV-triggered FVH cases in this international cohort were due to preexisting auto-Abs. This finding highlights auto-Abs against type I IFNs as a major determinant of HSV-FVH and paves the way for targeted preventive or therapeutic interventions. © 2025 Gervais et al. | |
| dc.description.fulltext | No | |
| dc.description.harvestedfrom | Manual | |
| dc.description.indexedby | WOS | |
| dc.description.indexedby | Scopus | |
| dc.description.indexedby | PubMed | |
| dc.description.publisherscope | International | |
| dc.description.readpublish | N/A | |
| dc.description.sponsoredbyTubitakEu | EU | |
| dc.description.sponsorship | The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, The Rockefeller University, the St. Giles Foundation, the National Center for Advancing Translational Sciences (NCATS), the French Agence Nationale de la Recherche (ANR) under France 2030 program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the ANR-RHU COVIFERON Program (21-RHUS-0008), ANR GENVIR (ANR-20-CE93-003), AI2D (ANR-22-CE15-0046) projects, the French Foundation for Medical Research (FRM) (EQU202503020018), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 101057100 (UNDINE), the Square Foundation, Grandir – Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the Battersea & Bowery Advisory Group; William E. Ford, General Atlantic’s Chairman and Chief Executive Officer; Gabriel Caillaux, General Atlantic’s Co-President, Managing Director and Head of Business in EMEA; and the General Atlantic Foundation; the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM, Paris Cité University, and the Imagine Institute. Paul Bastard was supported by the “Poste CCA-INSERM-Bettencourt” (with support from the Bettencourt-Schueller Foundation). Adrian Gervais was supported by a French government grant from the French National Agency for Research as part of the ANR-10-LABX-62-IBEID program. The Borghesi group, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, is supported by grants from the Italian Ministry of Health, RC08061819 and RC08061822, and by 5X1000 grant 08061821 from San Matteo Hospital. The Acute Liver Failure Study Group, which provided sera for the majority of ALF patients and was represented by Drs. Lee and Rule, was funded by the US National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) grants, R-01-DK-58369 and U-01-DK-58369. Nils Landegren was supported by the Swedish Research Council (no. 2021-03118). | |
| dc.description.version | Published Version | |
| dc.identifier.WoSQuartile | Q1 | |
| dc.identifier.doi | 10.1084/jem.20251760 | |
| dc.identifier.eissn | 1540-9538 | |
| dc.identifier.embargo | No | |
| dc.identifier.grantno | 101057100 | |
| dc.identifier.issn | 0022-1007 | |
| dc.identifier.issue | 3 | |
| dc.identifier.pubmed | 41348319 | |
| dc.identifier.scopus | 2-s2.0-105023913013 | |
| dc.identifier.uri | https://doi.org/10.1084/jem.20251760 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14288/32963 | |
| dc.identifier.volume | 223 | |
| dc.identifier.wos | 001631819500001 | |
| dc.keywords | Fulminant viral hepatitis (FVH) | |
| dc.keywords | Herpes simplex virus (HSV) | |
| dc.keywords | Type I interferons (IFNs) | |
| dc.keywords | Autoantibodies (auto-Abs) | |
| dc.keywords | Inborn errors of immunity | |
| dc.language | eng | |
| dc.publisher | Rockefeller University Press | |
| dc.relation.affiliation | Koç University | |
| dc.relation.collection | Koç University Institutional Repository | |
| dc.relation.ispartof | The Journal of experimental medicine | |
| dc.relation.openaccess | N/A | |
| dc.rights | N/A | |
| dc.rights.uri | N/A | |
| dc.subject | Immunology | |
| dc.subject | Medicine | |
| dc.title | Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis | |
| dc.type | Journal Article | |
| dspace.entity.type | Publication | |
| relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
| relation.isOrgUnitOfPublication | 91bbe15d-017f-446b-b102-ce755523d939 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
| relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
| relation.isParentOrgUnitOfPublication | d437580f-9309-4ecb-864a-4af58309d287 | |
| relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |
